MET targeted therapy for lung cancer: clinical development and future directions

about

Targeted Lung Cancer Treatments and Eye Metastasis

P2860

Q33566410-2F0A2FCA-CB4C-4884-AF2A-B6D8B2BAF7BF

P2860

MET targeted therapy for lung cancer: clinical development and future directions

Item

http://www.wikidata.org/entity/Q37645240

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

MET targeted therapy for lung cancer: clinical development and future directions

@en

MET targeted therapy for lung cancer: clinical development and future directions.

@nl

type

Item

label

MET targeted therapy for lung cancer: clinical development and future directions

@en

MET targeted therapy for lung cancer: clinical development and future directions.

@nl

prefLabel

MET targeted therapy for lung cancer: clinical development and future directions

@en

MET targeted therapy for lung cancer: clinical development and future directions.

@nl

P1476

MET targeted therapy for lung cancer: clinical development and future directions

@en

P2093

Patrick C Ma

http://www.w3.org/2001/XMLSchema#string

Yan Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Structure of the semaphorin-3A receptor binding module

The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

P304

53-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/LCTT.S23423

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28210125

http://www.w3.org/2001/XMLSchema#string

P932

5312490

http://www.w3.org/2001/XMLSchema#string

MET targeted therapy for lung cancer: clinical development and future directions

about

P2860

P2860

MET targeted therapy for lung cancer: clinical development and future directions

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932